SCV-07

Known as: SCV 07, SCV07 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2017
0120032017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The latency and amplitude of the auditory evoked Р300 potential were measured in 25 elderly and old persons without any cognitive… (More)
Is this relevant?
2011
2011
Gamma-D-glutamyl-L-tryptophan (SCV-07) demonstrated an overall efficacy signal in ameliorating oral mucositis (OM) in a clinical… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2011
2011
5592 Background: Gamma-D-glutamyl-L-tryptophan (SCV-07) is being studied for attenuation of oral mucositis in head and neck… (More)
Is this relevant?
2011
2011
5591 Background: Gamma-D-glutamyl-L-tryptophan (SCV-07) is being studied for attenuation of oral mucositis (OM) in head and neck… (More)
Is this relevant?
2010
2010
OBJECTIVE To evaluate the efficacy of a novel immunomodulating peptide (SCV-07) in attenuating the course of radiation-induced… (More)
Is this relevant?
Review
2009
Review
2009
Interferons are first immunomodulatory molecules that have been shown to display a wide range of applications due to their… (More)
Is this relevant?
2008
2008
Herpes simplex virus type 2 (HSV-2) infections produce a recurrent disease state associated with susceptibility to other… (More)
Is this relevant?
Review
2006
Review
2006
SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential… (More)
Is this relevant?
2004
2004
Gamma-D-Glutamyl-L-tryptophan (SCV-07) is a prospective medicine for the treatment of tuberculosis, according to the phase two… (More)
Is this relevant?
2003
2003
SCV-07 (gamma-glutamyl-tryptophan) is a new immunomodulatory compound that was developed and patented both for composition and… (More)
Is this relevant?